As part of a consolidation of its three Dublin plants into two
Clondalkin Pharma & Healthcare Ireland is to cut around 7% of its workforce in the region after unveiling plans to consolidate its operations in Dublin.
The company says it will consolidate from its present three production sites in Dublin to two production sites by absorbing the Clonshaugh facility into the Glasnevin and Cherry Orchard facilities.
Clondalkin Pharma & Healthcare’s chief executive David Lennon said the consolidation is a ‘strong and positive development in our continuous business improvement strategies’.
The Dublin sites are in close proximity within the M50 catchment area and they operate shared platforms in products, technologies and customer markets.
Lennon added that customers would benefit from scale and specialisation benefits and the elimination of duplication of overheads. Streamlining and combining production activities will also enhance capacity utillisation.
The company is backing the move by making ‘significant investments’ in new digital print technologies and in upgrading its facilities at Glasnevin and Cherry Orchard.
The Dublin businesses will continue to supply customers in institutional, commercial and pharmaceutical & healthcare markets, offering a combination of design, pre-press, printing, finishing and delivery capabilities and technologies to the highest PS 9000 and cGMP standards. The Cherry Orchard site was recently awarded the PS9000:2011 accreditation, the first such accreditation awarded globally.
‘In all our businesses we strive to offer sustainable employment,’ added Lennon. ‘We are confident that the product and service offering from the enlarged Glasnevin and Cherry Orchard production facilities will promote good employment opportunities in the future.’